---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-006886"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2022-03-22T23:59:59+00:00"
generated_at: "2026-06-26T20:38:18.975979+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exagen reports FY 2021 revenue up 15% to $48.3M; guides FY 2022 revenue $51-53M

## Summary
- Record 128,246 AVISE CTD tests in 2021; Q4 2021 test volume 34,147 (+21% YoY).
- Full-year testing revenue $47.1M (+27.8% YoY); Q4 testing revenue $12.5M (+14.2% YoY).
- FY 2021 net loss $26.9M vs $16.7M in 2020; cash $99.4M at year-end.
- Guidance: FY 2022 revenue $51M-$53M, implying 6-10% growth over 2021.
- Added Centene/WellCare coverage for 22M lives; now 91M in-network lives; acquired AVISE RADR license.

## SEC filing metadata
- accession: 0001628280-22-006886
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2022-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000162828022006886/0001628280-22-006886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000162828022006886/exdx-20220322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-006886
- JSON: https://secwatch.observer/filing/0001628280-22-006886.json
- Plain text: https://secwatch.observer/filing/0001628280-22-006886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.